F-1: Akanda Corp. Eyes $1.5 Million Capital Raise Through Share and Warrant Offering

Akanda Corp. announces a proposed public offering of common shares and pre-funded warrants to raise $1.5 million for capital expenditures, working capital, and potential acquisitions.

Summary

• Akanda Corp., a cannabis cultivation, manufacturing, and distribution company, is planning a public offering to raise up to $1.5 million.
• The offering includes common shares and pre-funded warrants, with the final price per share to be determined through negotiation with underwriters.
• The company intends to use the net proceeds for capital expenditures, operating capacity, working capital, general corporate purposes, refinancing existing debt, and potential acquisitions.
• Akanda's common shares are currently listed on the Nasdaq Capital Market under the symbol AKAN.
• The company is organized under the laws of the Province of Ontario, Canada, and is classified as an emerging growth company and a foreign private issuer under U.S. securities laws.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is actively seeking growth through capital raising and strategic initiatives, it also acknowledges significant risks and financial challenges, including a limited operating history and concerns about its ability to continue as a going concern.

Positives

• Canmart holds a Controlled Drug License in the UK, renewed on May 24, 2024.
• Akanda has the right to develop a Canadian farming property in British Columbia for THC and CBD facilities.
• The company is targeting the growing international medical cannabis market.
• Canmart has shifted its plan to providing third party and specialist import and distribution services for Schedule 2 products including CBPMs.

Negatives

• Investing in Akanda's securities is highly speculative and involves a high degree of risk.
• The company has a limited operating history and minimal revenues to date.
• The company's financial situation raises substantial doubt about its ability to continue as a going concern.
• The company has incurred aggregated outstanding loans, including accrued interest, of approximately $315,000 from Halo making Halo a significant creditor of the Company.

Risks

• The company's limited operating history and minimal revenues pose a significant risk.
• Changes in cannabis laws, regulations, and guidelines could adversely affect the company.
• The company faces potential exposure to product liability claims and actions.
• The company's ability to maintain its Nasdaq listing is uncertain.
• The company may be unable to effectively manage future growth.

Future Outlook

The company intends to use the net proceeds from this offering for capital expenditures, operating capacity, working capital, general corporate purposes and the refinancing or repayment of existing indebtedness and acquisitions of complementary products, technologies or businesses.

Industry Context

The announcement reflects a company in the cannabis sector seeking capital to expand its operations in a growing but highly regulated international market. The company's focus on the medical cannabis market aligns with the increasing global acceptance and legalization of cannabis for medical purposes.

Comparison to Industry Standards

• Comparable companies in the cannabis industry, such as Aurora Cannabis and Canopy Growth, have also raised capital through public offerings to fund expansion and operations.
• The focus on EU GMP certification aligns with industry standards for exporting medical cannabis to European markets, similar to companies like Tilray and Organigram.
• The company's strategy of acquiring or partnering with companies that have established distribution networks is a common approach in the cannabis industry, as seen with companies like Curaleaf and Green Thumb Industries.

Legal Proceedings

• The company is involved in ongoing litigation with its former Executive Chairman, Louisa Mojela.
• The company is involved in ongoing litigation with its former CFO, Shailesh Bhushan.
• Dentons UK and Middle East LLP (Dentons) filed a claim against Canmart for legal services and advice invoiced between July 2022 and November 2022.

Related Party Transactions

• The company has outstanding loans from Halo, a related party, totaling approximately $315,000.
• The company has a loan outstanding to 1248787 B.C. Ltd., a company controlled by Jatinder Dhaliwal, a director of the Akanda.

Stakeholder Impact

• Shareholders face potential dilution from the issuance of new shares and warrants.
• Employees may be affected by the company's ability to secure funding and execute its business plan.
• Customers may benefit from the company's expansion of its distribution network and product offerings.

Next Steps

• Negotiate the final public offering price per Common Share with the underwriters.
• Secure sales to patients while establishing or acquiring distribution channels in the U.K. domestic market.
• Obtain licenses for THC cultivation, CBD cultivation, and hemp cultivation at the BC Farm Operations.

Key Dates

Keywords

Akanda Corp, public offering, common shares, pre-funded warrants, medical cannabis, Canmart, capital raise, cannabis